

GLOBAL BENCHMARK · 2026

AI Companies Actually Printing **Revenue** in 2026

Not cloud infrastructure. Not copilots bolted onto software that was already selling. The AI-native companies whose entire business is the AI output itself.

What's actually inside

01 The filter: what counts as "purely AI revenue"

02 Nine companies, real 2026 ARR figures

03 The pricing pattern behind all nine

04 The ARR inflation caveat

05 What it means for enterprise buyers

Three things this list deliberately excludes

→ **Cloud infrastructure revenue**

AWS, Azure, Google Cloud, foundation-model API layers

→ **Seat-priced copilots bolted onto existing software**

AI features added to products that were already selling

→ **Anything where AI is a retention lever, not the product**

What's left: AI-native companies selling the output itself

\$19B

of the \$37B enterprises spent on generative AI in 2025 went to applications, not infrastructure

More than half of enterprise genAI spend now goes to the application layer, and at least 10 AI products have already crossed \$1B in ARR. Source: Menlo Ventures, 2025 State of Generative AI in the Enterprise.

\$4B

ARR by June 2026, three years after launch, up from roughly \$100M in January 2025

SpaceX acquired Anysphere for \$60 billion in an all-stock deal that closed in August 2026, the largest venture-backed startup acquisition on record. Source: CNBC.

Nine AI-native companies, 2026 ARR

Cursor (Anysphere)

AI coding agents

~\$4B

ElevenLabs

Voice AI

\$600M

Midjourney

Image generation

~\$500-600M

Perplexity

AI answers & agents

\$450M+

Harvey

Legal AI

~\$195-200M

OpenEvidence

Clinical decision support

~\$300M

Sierra

Customer service agents

\$200M

Abridge

Medical documentation

\$100M+

TERENCEKOK.COM · AI STRATEGY

THE PATTERN

07 / 10

Nobody on that list charges per seat

→ **Harvey prices per matter and document**

Sierra and customer service agents price per resolution

→ **Abridge prices per patient encounter**

ElevenLabs, Cursor and Perplexity price against usage

→ **OpenEvidence charges the user nothing at all**

Revenue comes entirely from pharma advertising against queries

40%

of enterprise SaaS spend will shift to usage-, agent- or outcome-based pricing by 2030

Seat-based licensing's share of enterprise SaaS revenue falls from 21% to 15% over the same period, with roughly \$234B of application spend exposed to this repricing. Source: Gartner, July 2026.

TERENCEKOK.COM · AI STRATEGY

[READ THE FINE PRINT](#)

09 / 10



We've seen companies where contracted ARR is 70% higher than ARR, even though a significant chunk of that contracted revenue will never actually materialize.

An investor, quoted in TechCrunch's reporting on inflated AI startup ARR, May 2026

TERENCEKOK.COM · AI STRATEGY

ENTERPRISE AI REVENUE BENCHMARK

10 / 10

**Check how a vendor prices
before you check what it **dem**os.**

A seat-priced assistant has no incentive to make itself good enough that you need fewer seats. An outcome-priced product has the opposite incentive. That

alignment is the real signal.



Terence Kok
AI & Innovation Strategist

[SAVE](#) · [COMMENT](#) · [FOLLOW](#)